Member Info for BasilAlderman

Yes, the message is clear HE1 as of today has a commercial discovery. Massive news.

A X 10 at 16p = a MCAP of £215 Million approx. That's peanuts in our sector. Suggest we think bigger at 80p - 150p a share as a target, certainly not 10p! As Haywain points out CAR-T, CDX and CBR are game changers in the sector. What value will big pharma pay for a licencing or takeover deal? That is the question we should be asking. If other deals in the pharma sector are anything to go by we are talking hundreds of millions at least.

Yes, quite right. People are missing the future intrinsic value of the HEMO asset. e.g. focus on a X 10 from today at 16p and a MCAP of £215 Million approx. That is still peanuts in our sector when small bio companies are being acquired for billions. You should be focusing on 80p - 150p a share as a target, not 3p!

Hi Mr I, your point about Eli Lilly is really interesting. Did you know that they acquired Morphic 4 weeks ago for $3.2 billion? Apparently Lilly bought the company for "MORF-057", Morphic’s clinical candidate for bowel disease. In summary, big bucks are being paid by the major pharma players to get a foothold in to new areas and to shore up expiring pipelines.

Yes and there have been quite a few pre-clinical and clinical stage companies acquired this year by big pharma for billions of pounds:

1. Roche paid $2.7 Billion to buy clinical-stage company Carmot Therapeutics a few months ago.

2. Also in 2024 Johnson & Johnson paid $2 Billion for Ambrx, another clinical stage company.

3. AND also this year Astra Zeneca paid $1 Billion for Amolyt, yet another clinical-stage pharma.

In summary, big bucks are being paid for pharma minnows like HEMO.

I see another of his favs ROAD is up X 8 over the last few months from 2.5p to 22p. Lets hope the same X 8 happens with SAR this year. Keep the research coming! Those buy out deals in our space make for very encouraging reading.

Yes, Longsuffering, when the company you invest in says the following you know you are on to a winner:

1. HE1 has declared a helium discovery.

2. HE1 plans to drill up to 30 wells in the area.

3. HE1 has working capital funding until June 2025.

4. Banks & offtakers will be financing the business moving forwards.

5. EWT successfully flowed a sustained average of 5.5% helium and up to a maximum of 7.9% helium (air corrected).

6. The well flowed naturally at a maximum flow rate of 2,701 barrels per day ("bpd").

7. Internal modelling demonstrates that this could increase to 20,000 bpd of fluid with artificial lift.

8. The fractured Basement interval flowed naturally for a period of six days with helium gas in solution, and little air contamination in what has been determined to be a pure helium/nitrogen mix.

9. Financial modelling demonstrates positive project economics with artificial lift and additional development wells.

10.HE1 is finalising its feasibility study ahead of submitting a Mining Licence ("ML") application by 17.9.24.

11. HE1 has agreed to acquire a 50% interest in Blue Star Helium's Galactica-Pegasus project.

12. The Galactica project contains confirmed discovery wells flowing up to 6% helium.

13. Initial 6 development well programme planned for Q4 2024 & on stream and producing in H1 2025

14. Acquisition builds a diversified helium company in USA and Tanzania.

15. Itumbula has a prolific surface helium seep which has been measured at up to 10.4% helium.

Points 1 - 15 clearly demonstrate that HE1 is the real deal and probably the biggest opportunity on AIM in many years.

PCS1954 and Brighty, there are quite a few pre and clinical stage companies in that excellent list. Thanks. It's very encouraging to read M&A activity continues at such a pace in our space.

1. Roche paying Carmot Therapeutics, a clinical-stage company $2.7 billion also piqued my interest

2. As did the $2 Billion paid by J&J for Ambrx, another clinical stage company

3. Plus as you say the $1 Billion paid by Astra Zeneca for Amolyt, yet another clinical-stage pharma, bodes well.

Thanks for posting that information as it's a cracking list of recent takeovers to focus the mind on what might be possible here sooner rather than later.

Yes, the FACT is that HE1 has no requirement to raise further funds at present as it has a working capital runway for a minimum of 12 months from the date of admission. i.e. June 2024, which takes us to June 2025. The exact wording can be found in the RNS, link below, but for clarity it clearly states:

"Following the completion of the proposed Fundraise, the Company will be fully funded to complete the EWT, with a working capital runway for a minimum of 12 months from the date of Admission".

https://polaris.brighterir.com/public/helium_one/news/rns/story/x27qjnw

Yes, CEO Lorna Blaisse confirmed in the interview last week that banks and offtakers will be financing this not a raise. Verbatim. This will happen after the mining license has been awarded, she added during the interview. It's pretty clear what the strategy is going to be moving forwards if you watch and listen to the interview and read the various announcements. i.e. banks and offtakers are going to be financing HE1. Happy days indeed, as you say!

Yes, most on this chat board are invested for the mega multi bag opportunity of a x 10 from here, at least. The shame for those that sold is that there was lot of disinformation last week about cash raises after the EWT and mining licence application. The FACT is that HE1 has no requirement to raise further as it has a working capital runway for a minimum of 12 months from the date of admission. i.e. June 2024, which takes us to June 2025.

You can read it in the RNS dated 10th June 2024. The unequivocal wording can be found in the section titled "Drilling Programme and related timetable".

It clearly states: "Following the completion of the proposed Fundraise, the Company will be fully funded to complete the EWT, with a working capital runway for a minimum of 12 months from the date of Admission".

The exact wording can be found in the RNS, link below:

https://polaris.brighterir.com/public/helium_one/news/rns/story/x27qjnw

Lets all chill and watch the share price / mcap deliver for all shareholders with a JV or takeover in due course. "You've got to be in it to win it". i.e. A X10 from here is more than attainable.

Some interesting mentions on here about China's interest in Tanzania and by default HE1 and its Helium discovery. For those that don't know, China, is already investing in Tanzania already in a big way. e.g.

1. Mining: China's Sichuan Hongda Group partnered with Tanzania's National Development Corporation to develop an iron and coal mine. Tanzania and China's Fujian Hexingwang Industrial Co. also signed a $77.4 million agreement to develop an iron ore project.

2. Infrastructure: The EXIM Bank of China has approved 11 billion RMB in funds to finance projects in Tanzania, including the National ICT Broadband Infrastructure Project, the Mtwara-Dar Gas Pipeline, and the Zanzibar International Airport Terminal.

3. Agriculture: Tanzania has benefited from Chinese investment and financing in agricultural products processing, irrigation farming, and water harvesting.

4. Manufacturing: Tanzania has benefited from Chinese investment and financing in building material manufacturing and the production of diesel engines and farm implements.

5. Tourism: Tanzania is identifying China as a strategic tourism market.

I.e. the comments on here about a possible link to a Chinese investment in HE1 are not as far fetched as you might think.

Yes, brilliant update at last.

1. Hemo is pleased to announce the successful completion of the development of a clinical-grade assay ("Assay") designed to assess FLT3 protein expression in acute myeloid leukemia ("AML") cells.

2. Assessing FLT3 protein expression in AML cells is crucial for the accurate identification and recruitment of patients for the imminent Phase I clinical trials of the Company's HEMO-CAR-T product candidate.

3. The trials are expected to commence shortly at MD Anderson Cancer Center ("MD Anderson"), one of the world's most respected centers devoted exclusively to cancer patient care, research, education and prevention.

4. The Phase I clinical trials are planned to expand to the University of Pennsylvania Medical Center thereafter.

5. CEO Quote: "The completion of our FLT3 assay marks a critical milestone in advancing our HEMO-CAR-T product candidate into clinical trials. This Assay will ensure we can accurately identify and recruit the right patients for the trials, bringing us one step closer to providing a potentially life-saving treatment for those battling AML. We are excited to begin our Phase I trials imminently at MD Anderson Cancer Center, a leading institution in cancer care, and look forward to expanding our efforts to the University of Pennsylvania Medical Center."

i.e. Getting closer and closer to BIG news from HEMO.

N4P appoints Dr Michael Palfreyman with immediate effect.

1. He has 4 decades of successful drug discovery and development experience in several therapeutic areas with two major pharmaceutical companies (Marrion Meryl Dow, now Sanofi, and Beecham Pharmaceuticals, now GSK)

2. Co-founded and developed several biotechnology companies including, among others, Co-Founder of Scriptgen (Anadys) Pharmaceuticals which was sold to Roche in 2011 for US$230 million and Co-Founder and CSO of Amorsa Therapeutics, Inc. developing novel treatments for depression and pain where he oversaw a successful US$180 million exit.

3. Currently advises Cybin Inc. listed on the New York Exchange (NYSE: CYBN) and was Chairman and COO to Adelia Therapeutics Inc. that merged in 2020 to form the current Cybin Inc.

4. Has served on various scientific advisory boards and has been an adviser to The Forsyth Institute, Stanford Research Institute, NeuroNascent, MAK Scientific and Jasco Pharmaceuticals.

This is an interesting arrival at N4P, to say the least!

HE1 has a working capital runway for a minimum of 12 months from the date of admission. i.e. June 10th 2024, which takes us to June 2025.

You can read it in the RNS dated 10th June 2024. The unequivocal wording can be found in the section titled "Drilling Programme and related timetable".

It clearly states: "Following the completion of the proposed Fundraise, the Company will be fully funded to complete the EWT, with a working capital runway for a minimum of 12 months from the date of Admission".

The exact wording can be found in the RNS, link below:

https://polaris.brighterir.com/public/helium_one/news/rns/story/x27qjnw

Yes, follow the money: 5 Million BUY

05-Sep-24 13:04:56 1.14 5,000,000 Buy* 1.13 1.14 57.00k

All the information was in the RNS yesterday. i.e. HE1 has declared a helium discovery and plans to drill up to 30 wells in the area. Anyway, it's good to see the CEO today confirming the actual facts contained in that RNS via the interview. The interview should also help stop the misinformation in its tracks.

Yes, industry giants such as Linde, Exxon, Messer, APD, Siemens, Air Liquide, Helium24, Glencore or Trafigura could be approaching HE1 very soon. It doesn't take a rocket scientist to see one of these major players doing a deal with HE1 now. All the major helium players will be very aware now of HE1's helium discovery at Itumbula that was RNS'd yesterday.

Yes Markie, CEO Lorna Blaisse confirming just now in that interview that banks and offtakers will be financing this not a raise. This will happen after the mining license has been awarded, she also repeated during the interview.

Haha Happy. You didn't read the RNS then did you!!! I've pasted it below as HE1 confirmed a helium discovery yesterday and big plans to drill up to 30 helium wells in the area. Stop misleading folks on here and stick to what the RNS actually said:

Helium One Global (AIM: HE1), the primary helium explorer in Tanzania, is pleased to confirm a helium discovery following completion of its extended well test ("EWT") operations at Itumbula West-1 ("ITW-1") which successfully flowed a sustained average of 5.5% helium (air corrected) from the fractured Basement and flowed a sustained average of 5.2% helium (air corrected) to surface from the faulted Karoo Group.

· Successful completion of EWT operations at ITW-1 and demobilisation now underway

· Fractured Basement interval flowed a sustained average of 5.5% helium (air corrected) to surface and up to a maximum of 6.7% helium (air corrected)

· Faulted Karoo Group interval flowed a sustained average of 5.2% helium (air corrected) to surface and up to a maximum of 7.9% helium (air corrected)

· The fractured Basement interval also flowed up to 1.1% hydrogen to surface

· The well flowed naturally at a maximum flow rate of 2,701 barrels per day ("bpd") of fluid on a 36/64ths of an inch choke setting which equates to 834 standard cubic feet per day ("scf/d") of helium

· Internal modelling demonstrates that this could increase to 20,000 bpd of fluid with artificial lift in the development phase. On this basis, the Company estimates the actual flow rate would increase to 6,176 scf/d of helium, when applying an average concentration of 5.5% helium

· The fractured Basement interval flowed naturally for a period of six days with helium gas in solution, and little air contamination in what has been determined to be a pure helium/nitrogen mix

· Gas samples were also collected for additional laboratory analysis when required

· Preliminary internal financial modelling demonstrates positive project economics with artificial lift and additional development wells

· The Company is now integrating the results of the EWT and finalising its feasibility study ahead of submitting a Mining Licence ("ML") application

· Zero Lost Time Injuries ("LTI") during the EWT operations at ITW-1

· Non-productive time ("NPT") for the Company owned Epiroc Predator 220 drilling rig during EWT operations was 2.5%

Lorna Blaisse, Chief Executive Officer, commented:

"This is yet another huge milestone for the Company and we are delighted to have successfully flowed helium, of significant concentration, to surface from both intervals during the EWT. The well was flowed naturally during the testing and based on the recorded flow rates, with the addition of artificial lift in the production phase this becomes a globally significant helium project in southern Rukwa.

See the foot of the RNS too titled, "Next Steps" also for information about up to 30 he